Genmab A (GMAB) Asset Writedowns and Impairment (2024 - 2025)

Genmab A (GMAB) reported Asset Writedowns and Impairment of $1.0 million for Q3 2025, down 90.91% on a YoY basis from $11.0 million in Q3 2024, and little changed quarter-over-quarter from $1.0 million in Q2 2025.

Genmab A (GMAB) Asset Writedowns and Impairment (2024 - 2025) Analysis & Trends

Genmab A has reported Asset Writedowns and Impairment for 2 years, with the latest figure at $1.0 million in Q3 2025.

  • For the quarter ending Q3 2025, Asset Writedowns and Impairment fell 90.91% year-over-year to $1.0 million; the trailing twelve-month figure through Sep 2025 stood at $14.0 million (changed N/A YoY), and the FY2025 full-year result was $32.0 million, up 88.24% from the prior year.
  • Asset Writedowns and Impairment for Q3 2025 stood at $1.0 million, roughly flat from $1.0 million in the prior quarter.
  • The five-year high for Asset Writedowns and Impairment was $11.0 million in Q3 2024, with the low at $1.0 million in Q1 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 723,416.35 Bn 723,416.32 Bn -
2 Belite Bio 57,340.00 Bn 57,340.00 Bn -
3 Quantum Biopharma 19,125.08 Bn 19,125.08 Bn -
4 Legend Biotech 3,262.00 Bn 3,261.71 Bn 242.10 Mn
5 Akari Therapeutics 1,789.67 Bn 1,789.67 Bn -
6 Evaxion A 1,480.39 Bn 1,480.37 Bn -
7 Psyence Biomedical 241.78 Bn 241.78 Bn -
8 Vertex Pharmaceuticals 113.54 Bn 106.29 Bn 2.59 Bn
9 Abivax 94.26 Bn 94.26 Bn -
10 Genmab A 48.34 Bn 46.82 Bn 831.00 Mn

Historic Data

Download Data
DateValue
Sep 30, 2025 1.00 Mn
Sep 30, 2025 1.00 Mn
Jun 30, 2025 1.00 Mn
Jun 30, 2025 1.00 Mn
Mar 31, 2025 1.00 Mn
Mar 31, 2025 1.00 Mn
Sep 30, 2024 11.00 Mn
Sep 30, 2024 11.00 Mn
Jun 30, 2024 9.00 Mn
Jun 30, 2024 9.00 Mn
Mar 31, 2024 9.00 Mn
Mar 31, 2024 9.00 Mn